Storia in 4 fonti

Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial

(Bloomberg) -- Roche Holding AG’s experimental lung cancer pill outperformed two approved medicines in a late-stage study, boosting the Swiss drugmaker’s bid to bring a next-generation treatment to market.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

swissinfo.chStai leggendo1 mese fa

Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial

originale

Timeline cronologica

giovedì 2 luglio 2026·biopharmadive.com
Roche KRAS drug succeeds in head-to-head lung cancer study
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
giovedì 2 luglio 2026·morningstar.com
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial

Confronto fonti

Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial

Timeline cronologica

Roche KRAS drug succeeds in head-to-head lung cancer study

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Roche’s lung cancer pill beats rivals in head-to-head Phase 3 study

Roche KRAS drug succeeds in head-to-head lung cancer study

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors…

Roche claims clinical trial success for lung cancer drug

Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial

Roche’s lung cancer pill beats rivals in head-to-head Phase 3 study